AzTrials
AzTrials

Macular TeleangiectasiaMacTEL-SuppNCT00568828

MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

An observational study of Macular Teleangiectasia and Macular Pigment, run by The Lowy Medical Research Institute Limited at 1 site in Germany.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Macular Teleangiectasia, Macular Pigment
How many people
12 participants
Where
1 siteGermany
Study dates
Dec 2007to Feb 2008
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 12 patients with Macular Teleangiectasia

Who may be able to join

  • Different distribution of macular pigment in patients with known macular teleangiectasia

Who cannot join

  • No

Trial locations and contacts

1 site in 1 country.

Daniel Pauleikhoff, MD contact

49-251-933080

dapauleikhoff@muenster.de

Germany1 site, 1 recruiting
  • Dep. of Ophthalmology, St. Franziskus Hospital

    Münster, 48145

    Meike Zeimer, MD, 49-251-933080, kpl-auge@muenster.de

    Recruiting

Other trials in Germany

About this study

Official title: Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

  1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
  2. investigate and quantify MP at the posterior pole of MACTEL probands
  3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin
Read the detailed description

Rationale for performing this study Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

  1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
  2. investigate and quantify MP at the posterior pole of MACTEL probands
  3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

The suggested study During this study we plan to select at least 10 MACTEL probands with different patterns of MP distribution including

  1. those with detectable accumulation of MP in the center and segmental reduction of MP temporally
  2. those with nearly no central accumulation and and larger area of reduced MP temporally
  3. those with no detectable accumulation of MP in the center and a halo of MP at a more eccentric location These probands will be supplemented with Lutein (L) and Zeaxanthin (Z) (12mg L and 1 mg Z, provided as esters, 120mg Vitamin C, 17.6 mg Vitamin E, 10mg Zink, 40µg Selen (Ocuvite Lutein™)) for a duration of nine months. During the supplementation and three months after stop of supplementation, probands will be investigated every three months including
  4. ophthalmologic investigation, 2. fundus photography, 3. measurement of MP with a modified Heidelberg retina Angiograph employing two excitation wavelengths (514 and 488nm) 4. measurement of L and Z in serum.

Aim of the study

  1. Investigation of changes of MP concentration and distribution following supplementation of L and Z in MACTEl probands
  2. How do serum levels of L and Z change in these probands?

Visit:

V1 Screening \& Start of supplementat V2 V3 V4 End of supplemenation V5 after stop of intake Months 0 3 6 9 12 general Informed consent X Medical history X in- and exclusion criteria X concommitant medication X X X X X Adverse events X X X X Pill count X X X Vital signs/ BMI X X Slitlamp investigation X X X X X Fundusphotography X X Visual acuity X X X X X Supplementation X X X Measurement of Xanthophylls Eye: MPOD (HRA) X X X X X Food frequency questionnaire X X Blood collection For (Heparin) Plasma to quantify Xanthophylls and Lipids X X X X X

Probands resident within a perimeter of 40km around the clinic will be preferentially selected to lower travel expenses. Recruitment takles place during regular visits in the course of the MACTEL study. For the angiography a vein will be punctated so that no additional punction is needed. Serum ist centrifuged at 1500g for 15min and kept at -70°C until analyse. Analyse of the Xanthophylls and Lipids in serum will be performed at the central laboratory of the University of Münster.

Autofluorescence imaging is part of study protocol for MACTEL Study. Two main images will be taken, one with an excitation wavelength of 488nm (good absorption by MP) and one with 514nm (poor absorption by MP). The digital subtration of both images provides a map of MP density around the fovea.

Inclusion criteria Informed consent Age at least 18y.? Type 2 IMT? Healthy general condition? At least one eye free from lens- or retina problems interfering with MP measurement with the modofied Heidelberg retina angiograph? Exclusion criteria No informed consent ? Younger than als 18 y.? Intake of Supplements containing L and Z (> 3mg L und >1mg Z) during the last 6 months? Bad general condition/ unintended loss of weight (>10%) within the last 3 monhs?

Keywords
Macular Teleangiectasia, Macular Pigment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Macular Pigment Optical Density

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2007 (estimated)
  2. Study startDec 2007
  3. Study completionFeb 2008 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
12 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00568828
Sponsor's protocol ID
MacTEL Supplement
Acronym
MacTEL-Supp
Status last verified
Dec 2007
First submitted
5 Dec 2007
Last updated
6 Dec 2007
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Macular Teleangiectasia and Macular Pigment, run by The Lowy Medical Research Institute Limited at 1 site in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Dec 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Daniel Pauleikhoff, MD (49-251-933080, dapauleikhoff@muenster.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Macular Pigment Optical Density (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2007.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in